Electra Therapeutics, Inc. (ETRA) reported initial holdings for its Chief Financial Officer Christopher William Clark, consisting of two employee stock options over common stock. One option covers 319,202 shares at $4.96 per share, expiring February 12, 2036, and is early exercisable with vesting beginning December 1, 2025. A second option covers 292,781 shares at $15.00 per share, expiring September 16, 2036, with monthly vesting commencing September 17, 2026.
Electra Therapeutics, Inc. (symbol: ETRA) is the issuer of record for a Form 3 filing submitted to the SEC.
Electra Therapeutics, Inc. (ETRA) reports the initial beneficial ownership of its President and CEO, Dong Quehuong (Kathy), consisting of multiple employee stock options and shares of Series A Convertible Preferred Stock, each convertible into common stock. The options cover several blocks of common shares with exercise prices ranging from $4.40 to $15.00 per share and expirations between March 23, 2032 and September 16, 2036, subject to detailed time-based vesting schedules and, for several grants, early exercisability with the issuer’s right of repurchase. The Series A Convertible Preferred Stock represents 455,484 underlying common shares that will automatically convert into common stock upon the closing of the company’s initial public offering, with 73,147 of those underlying shares identified as restricted shares subject to monthly vesting beginning September 16, 2026.